M-M-R II Rx
Generic Name and Formulations:
Measles, mumps and rubella viruses live, attenuated; for SC inj; contains neomycin, human albumin; preservative-free.
Merck & Co., Inc.
Indications for M-M-R II:
Measles, mumps and rubella immunization. A 2nd dose of measles vaccine is recommended.
Adults and Children:
<12 months: usually not recommended. Each dose is 0.5mL. Give by SC inj into upper outer arm. First dose at 12–15 months of age, second dose at 4–6yrs of age (ACIP recommendations).
Egg, gelatin, or neomycin hypersensitivity. Active respiratory or other febrile infection. Active untreated tuberculosis. Immunosuppression. Blood dyscrasias. Bone marrow or lymphatic malignancy. Pregnancy (Cat.C) during and for 3 months after vaccination.
Have epinephrine inj available. History of febrile convulsions or cerebral injury. Defer vaccination for at least 3 months after blood or plasma transfusions or immune serum globulin, and for at least 1 month before or after other live virus vaccines (except oral polio). Nursing mothers: not recommended.
Immunosuppressants (see Contraindications). May interfere with tuberculin test.
Fever, rash, malaise, sore throat, headache, local reactions, arthritic symptoms, parotitis, orchitis, thrombocytopenia, purpura; encephalitis (rare).
Single dose vial—1, 10 (w. diluent); Multi-dose vial—1 (w. diluent)
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL